Saffron

Names and identification

Language	Name
English	Saffron
Common Names	Saffron, Kesar
Hindi	Kesar, Zafran
Sanskrit	Kumkuma, Kashmirajanna
Latin/Botanical	Crocus sativus

Parts Used

• Stigma

Dosha Effects

Dosha	Effect
Vata	Decreases
Pitta	Decreases
Kapha	Decreases

Key Phytochemical Constituents

• Crocin
• Crocetin
• Safranal
• Picrocrocin

Therapeutic Actions (Karma)

• Antidepressant
• Antioxidant
• Neuroprotective
• Complexion enhancer
• Emmenagogue
• Aphrodisiac

How does it work?

• Crocin inhibits norepinephrine reuptake; safranal inhibits serotonin reuptake - dual monoamine reuptake inhibition underpins antidepressant activity.
• Increases brain-derived neurotrophic factor (BDNF) levels crucial for neurogenesis and synaptic plasticity.
• Crocin upregulates endogenous PACAP, activating ERK/CREB signaling cascade, improving synaptic plasticity and neuronal survival.
• Modulates BDNF/CREB/ERK signaling cascade relevant to behavioral changes in depression.
• NMDA receptor antagonism and GABA-A receptor agonism contribute to antidepressant and anxiolytic effects.
• CYP3A4 enzyme inhibition affects drug metabolism pharmacokinetics.
• Anti-inflammatory effects through suppression of pro-inflammatory cytokines.
• Neuroprotective activity of crocin, crocetin, and safranal through combined neurotransmitter regulation, anti-inflammatory effects, and direct neuroprotection.
• Active constituents: crocin (color/antioxidant), crocetin (anti-inflammatory), picrocrocin (taste), safranal (fragrance/serotonergic).

How is it used traditionally?

Most precious spice in Ayurveda. Used for Varnya (complexion), Vishodhan (purification), and Yoniroga (gynecological disorders). Kumkumadi Tailam is a famous face oil.

Where is it described in the classical texts?

• Charaka Samhita
• Bhavaprakasha Nighantu (Karpuradi Varga)

Modern Research (Meta-Analysis)

Total PubMed publications found: 3178

Key Research Papers

1. The Effects of

Authors: Seyedi-Sahebari Sepideh, Farhang Sara, Araj-Khodaei Mostafa et al. Journal: Journal of attention disorders (2024) PMID: 37864351

BACKGROUND AND AIM: METHOD: This study includes clinical trial studies that assessed the efficacy and/or safety of saffron in ADHD patients. Non-English papers, review articles, commentaries, letters, observational studies, thesis, animal studies, in-vitro studies, and conference abstracts were not included. The risk of bias in randomized studies was evaluated based on the Cochrane RoB.2, and risk of bias in pre-post intervention studies was assessed using the ROBINS-I tool. RESULTS: Four studies met our inclusion criteria with a total of 118 patients. The results manifested an efficient role of saffron as either an adjuvant therapy to MPH or a single therapy against ADHD, without significant safety issues. DISCUSSION: Saffron demonstrates promise in improving ADHD symptoms, with an accep…

Keywords: ADHD, Crocus sativus, attention deficit disorder with hyperactivity, saffron, systematic review

2. Saffron (

Authors: El Midaoui Adil, Ghzaiel Imen, Vervandier-Fasseur Dominique et al. Journal: Nutrients (2022) PMID: 35276955

Saffron (…

Keywords: age-related diseases, crocetin, crocins, crocus sativus, neuropsychiatric diseases, nutrients, picrocrocin, saffron, safranal

3. Saffron (Crocus sativus) for depression: a systematic review of clinical studies and examination of underlying antidepressant mechanisms of action.

Authors: Lopresti Adrian L, Drummond Peter D Journal: Human psychopharmacology (2014) PMID: 25384672

Saffron, a spice derived from the flower of Crocus sativus, has now undergone several trials examining its antidepressant effects and, in a recent meta-analysis, was confirmed to be effective for the treatment of major depression…

Keywords: Crocus sativus, antidepressant, depression, review, saffron

4. New horizons for the study of saffron (Crocus sativus L.) and its active ingredients in the management of neurological and psychiatric disorders: A systematic review of clinical evidence and mechanisms.

Authors: Han Shufen, Cao Yifei, Wu Xingrong et al. Journal: Phytotherapy research : PTR (2024) PMID: 38424688

Saffron (Crocus sativus), as an herbal medicine, has been extensively investigated for treating neurological and psychiatric disorders. This systematic review aimed to assess the overall effects of saffron on cognition, depression, anxiety, sleep disorders, attention-deficit/hyperactivity disorder (ADHD), and obsessive-compulsive disorder (OCD). Relevant randomized controlled trials (RCTs) were identified by searching PubMed/Medline, Web of Science, and Clinical Trials databases up to June 2023 according to search terms and inclusion criteria. The participants were either healthy or suffering from some diseases, including neurological and psychiatric disorders, and consumed saffron or its extracts as an intervention. The risk of bias was assessed according to the Cochrane guidelines, and t…

Keywords: ADHD, OCD, cognition, depression and anxiety, saffron, sleep disorders

5. None

Authors: Shamabadi Ahmad, Asadigandomani Hassan, Kazemzadeh Kimia et al. Journal: Medical hypothesis, discovery & innovation ophthalmology journal (2024) PMID: 39507811

Age-related macular degeneration (ARMD) leads to impaired vision and potential blindness. Globally, it accounts for approximately 9% of vision loss cases, and a projected 288 million individuals will be affected by 2040. Current treatments have limitations such as variable effectiveness, high costs, and potential side effects. Additionally, atrophic ARMD management remains challenging. As saffron has shown promising neuroprotective and antioxidant effects by potentially delaying disease progression, this study aims to review the mechanistic, pre-clinical, and clinical evidence of the effects, safety, and tolerability of saffron in ARMD treatment…

Keywords: adverse drug reaction, age related macular degeneration, clinical trial, crocus sativus, herbal medicine, macular degeneration, neuroimmunomodulation, nutraceuticals, saffron, saffron crocus

6. Effect of Saffron Versus Selective Serotonin Reuptake Inhibitors (SSRIs) in Treatment of Depression and Anxiety: A Meta-analysis of Randomized Controlled Trials.

Authors: Shafiee Arman, Jafarabady Kyana, Seighali Niloofar et al. Journal: Nutrition reviews (2025) PMID: 38913392

Saffron, a natural remedy with potential antidepressant and anxiolytic properties, has gained attention as a potential therapeutic option…

Keywords: Crocus sativus, anxiety, depression, saffron

7. Crocus sativus L. Versus Methylphenidate in Treatment of Children with Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind Pilot Study.

Authors: Baziar Sara, Aqamolaei Ali, Khadem Ebrahim et al. Journal: Journal of child and adolescent psychopharmacology (2019) PMID: 30741567

Attention-deficit/hyperactivity disorder (ADHD) is one of the most common neuropsychiatric disorders of childhood and adolescence. About 30% of patients do not respond to stimulants or cannot tolerate their side effects. Thus, alternative medication, like herbal medicine, should be considered. The aim of this trial is to compare the safety and efficacy of Crocus sativus (saffron) versus methylphenidate in improving symptoms of children with ADHD…

Keywords: attention-deficit/hyperactivity disorder, clinical trial, methylphenidate, saffron

8. Saffron (

Authors: Marrone Giulia, Urciuoli Silvia, Di Lauro Manuela et al. Journal: Nutrients (2024) PMID: 39064764

Keywords: Crocus sativus L., by-products, chronic kidney diseases, circular economy, depression, metabolic syndrome, natural bioactive compounds

What do recent clinical trials show?

• Han S, Cao Y, Wu X and others 2024. New horizons for the study of saffron (Crocus sativus L.) and its active ingredients in the management of neurological and psychiatric disorders: A systematic review of clinical evidence and mechanisms. Phytotherapy research : PTR. PMID 38424688 · doi:10.1002/ptr.8110
  Systematic review (through June 2023) assessing saffron’s effects on cognition, depression, anxiety, sleep disorders, ADHD, and OCD, confirming broad neuropsychiatric therapeutic potential.
• Dai L, Chen L, Wang W 2020. Safety and Efficacy of Saffron (Crocus sativus L.) for Treating Mild to Moderate Depression: A Systematic Review and Meta-analysis. The Journal of nervous and mental disease. PMID 32221179 · doi:10.1097/NMD.0000000000001118
  Meta-analysis found large effect size (M ES = 1.62, P < 0.001) for saffron vs. placebo in treating depressive symptoms. Null effect size (M ES = -0.15) vs. antidepressants, indicating comparable efficacy.
• Bathaei P, Imenshahidi M, Vahdati-Mashhadian N and others 2025. Effects of Crocus sativus and its active constituents on cytochrome P450: a review. Naunyn-Schmiedeberg’s archives of pharmacology. PMID 40167627 · doi:10.1007/s00210-024-03525-6
  Review cataloguing saffron and its constituents’ (crocin, crocetin, safranal) effects on CYP enzymes, particularly CYP3A4 inhibition, with implications for drug interaction prediction.
• Ziani A, Bekkouch O, Ouahhoud S and others 2025. Phytochemistry, Biological Activities, Molecular Mechanisms, and Toxicity of Saffron (Crocus sativus L.): A Comprehensive Overview. Antioxidants (Basel, Switzerland). PMID 41462633 · doi:10.3390/antiox14121433
  Comprehensive overview confirming saffron’s anti-inflammatory, antioxidant, neuroprotective, and anticancer properties with detailed toxicological profiling.
• Lu C, Ke L, Li J and others 2021. Saffron (Crocus sativus L.) and health outcomes: a meta-research review of meta-analyses and an evidence mapping study. Phytomedicine : international journal of phytotherapy and phytopharmacology. PMID 34419735 · doi:10.1016/j.phymed.2021.153699
  Meta-research review of meta-analyses mapping the full evidence landscape for saffron health outcomes across cardiovascular, metabolic, neurological, and other domains.

2 further claims previously listed here could not be traced to a published paper and have been removed. An absence here means we could not identify the source, not that no work exists.

Recent safety updates

• Doses up to 1.5 g/day considered safe. Toxic effects reported at 5 g. 10 g is abortive. 20 g is potentially lethal.
• Most clinical studies use 30-100 mg/day with good safety profile.
• CYP3A4 inhibition may increase toxicity of narrow therapeutic index drugs: digoxin, warfarin, cyclosporine A.
• Anticoagulant properties may increase bleeding risk when combined with warfarin, heparin, aspirin, or clopidogrel.
• May enhance effects of antidepressant medications - additive serotonergic effects require monitoring.
• Contraindicated in pregnancy due to uterine stimulant and abortifacient effects at high doses.
• Excessive consumption can cause dizziness, nausea, vomiting, uterine bleeding.
• LD50 values: 1.6 g/kg (stigma extract) and 6 g/kg (petal extract) in animal models.
• Saffron extract, safranal, and crocin have little or no acute toxicity at therapeutic doses.

Recommended Dosage

Stigma: 20-30mg/day (up to 1.5g/day in research); With milk: 2-3 strands

Safety, contraindications and cautions

• Pregnancy (high doses — uterine stimulant)
• Bipolar disorder
• Very expensive (adulteration risk)

What is it made of?

Part(s) Analyzed: Stigma

Key Active Markers

• Crocetin
• Crocin
• Safranal
• Picrocrocin

Analytical Methods: HPLC fingerprinting, TLC (identity), LC-MS/MS (marker quantification)

Dosage forms and preparation

Dosage Forms: Churna (powder), Tincture, Capsule, Kesar milk (traditional preparation), Soft gelatin capsule, Sublingual tablet, Ophthalmic solution

Standard Dosage: 20-100 mg standardized extract per day (typical clinical dose 30 mg/day for mood support); 50-200 mg dried stigma in traditional use; do not exceed 1.5 g/day

Bioavailability: Crocin (water-soluble carotenoid glycoside) has moderate oral bioavailability (15-25%); hydrolyzed to crocetin in the GI tract, which is the primary absorbed form with 50-65% bioavailability. Safranal is volatile and rapidly absorbed. Bioavailability improved with phospholipid complexation (Phytosome technology) and nanoemulsion formulations. Sublingual delivery bypasses first-pass metabolism for safranal.

Optimal Timing: Morning dose for mood and cognitive benefits; with warm milk at bedtime per traditional use (Kesar-Doodh)

Standardized Extract: Standardized stigma extract (affron or equivalent), NLT 3.5% Lepticrosalides (crocins + safranal combined); or standardized to NLT 2% crocin and NLT 0.3% safranal by HPLC-DAD

Shelf Life: 24 months for standardized extract capsules in aluminum blisters; 12-18 months for raw stigma (whole); 36 months for properly sealed nitrogen-flushed capsules

Storage: Store at 15-25 deg C in airtight, light-protected containers (amber glass or aluminum blisters). Nitrogen atmosphere recommended. RH <40%. Whole stigmas in sealed tins away from light, heat, and moisture.

Marker Compounds: Crocin-1 (trans-crocin-4), Crocin-2, Crocetin, Safranal, Picrocrocin, Kaempferol

Extraction Methods

• Aqueous extraction (cold maceration for crocin preservation)
• Hydroalcoholic extraction (40-50% ethanol)
• Supercritical CO2 for safranal-enriched fractions
• UAE (ultrasound-assisted extraction) for improved yield
• Enzyme-assisted extraction for enhanced crocin recovery

Synergistic Combinations

• Ashwagandha (antidepressant synergy, clinically validated)
• Brahmi (cognitive enhancement)
• Turmeric (anti-inflammatory synergy)
• Piperine (bioavailability enhancement for crocin)
• Sandalwood (Pitta-pacifying luxury formulations)